Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies

Annals of Pharmacotherapy

Volumn 44, Issue 3, 2010, Pages 479-488

  Hauber, A Brett ^a   Johnson, F Reed ^a   Grotzinger, Kelly M ^b   Özdemir, Semra ^c  

^a RTI INTERNATIONAL   (United States)

^b GLAXOSMITHKLINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

Chronic ITP; Conjoint analysis; Discrete choice experiment; Efficacy; Patient preference; Risk benefit; Safety

Indexed keywords

CORTICOSTEROID; LIVER ENZYME; STEROID;

ADULT; ARTICLE; CORTICOSTEROID THERAPY; DRUG CHOICE; DRUG EFFICACY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; PATIENT DECISION MAKING; PATIENT EDUCATION; PRIORITY JOURNAL; REBOUND; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOCYTE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; BLOOD PLATELETS; CHOICE BEHAVIOR; CHRONIC DISEASE; DATA COLLECTION; FEMALE; GLUCOCORTICOIDS; HUMANS; LIVER; MALE; MIDDLE AGED; PATIENT PREFERENCE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 77749345764     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M567     Document Type: Article

References (28)

1. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 2009;150:516-27.
2. Avorn J, Shrank WH. Communicating drug benefits and risks effectively: there must be a better way. Ann Intern Med 2009;150:563- 4.
3. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
4. McMillan R. Therapy for adults with refractory chronic immune idiopathic thrombocytopenic purpura. Ann Intern Med 1997;126:307-14.
5. Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6:711-2
6. Provan D, Newland A. Idiopathic thrombocytopenic purpura in adults. J Pediatr Hematol Oncol 2003;25:S34-8.
7. Provan D, Newland A, Bolton-Maggs P, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-96.
8. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3- 46.
9. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504-22.
10. Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002;118:933- 4.
11. George JN, Vesely SK. How can we provide the best care for our patients with immune thrombocytopenic purpura? Mayo Clinic Proc 2004;79:456-7.
12. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-51.
13. Ryan M, Farrar S. Using conjoint analysis to elicit preferences in health care. BMJ 2000;320:1530-3.
14. Bridges JFP, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. Patient 2009;1:1-10.
15. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769-79.
16. Lipkus I, Hollands J. The visual communication of risk. J Natl Cancer Inst Monogr 1999;25:149-63.
17. Krupnick A, Alberini A, Cropper M, et al. Age, health and the willingness to pay for mortality risk reductions: a contingent valuation survey of Ontario residents. J Risk Uncertain 2002;24:161-86.
18. Train K. Discrete choice methods with simulation. Cambridge, England: Cambridge University Press, 2003.
19. Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, eds. Applications of simulation methods in environmental and resource economics. Dordrecht, Netherlands: Springer Publisher, 2005.
20. Johnson FR, Ozdemir S, Hauber AB, Kauf T. Women's willingness to accept perceived risks for vasomotor symptom relief. J Womens Health 2007;16:1028-40.
21. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-34.
22. Product information. WinRho SDF (rho(D) immune globulin intravenous [human]). Deerfield, IL: Baxter Pharmaceuticals, 2006. www.baxter.com/products/ biopharmaceuticals/downloads/winrhopi.pdf 13 (accessed 2009 Mar 13).
23. Product information. Gammagard S/D (immune globulin intravenous [human]). Deerfield, IL: Baxter Pharmaceuticals, 2007. www.rxlist.com/cgi/generic/ gammagard.htm (accessed 2007 Dec 13).
24. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991;77:1884-93.
25. Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rho(D)). Blut 1984;49:29-35.
26. Salama A, Kiefel V, Mueller-Eckhardt C. Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol 1986;22:241-50.
27. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983;2:193-5.
28. Kahneman D, Tversky A. Prospect theory: an analysis of decisions under risk. Econometrica 1979;47:313-27.